It has been long assumed that DNA damage is induced in a linear manner with respect to the dose of a direct acting genotoxin. Thus, it is implied that direct acting genotoxic agents induce DNA damage at even the lowest of concentrations and that no "safe" dose range exists. The linear (non-threshold) paradigm has led to the one-hit model being developed. This "one hit" scenario can be interpreted such that a single DNA damaging event in a cell has the capability to induce a single point mutation in that cell which could (if positioned in a key growth controlling gene) lead to increased proliferation, leading ultimately to the formation of a tumour.
Please cite this article in press as: Jenkins, G.J.S., et al., Genotoxic thresholds, DNA repair, and susceptibility in human populations. Toxicology implies no safe low dose. Note the line does not go through the origin, as background mutation levels are detectable in vitro and in vivo. The shaded area represents the background level (historial background ranges can define this region). Thresholded responses are depicted by the dotted line in the low dose range. At the low dose region no increase over background mutation level is seen, followed by a critical dose range where mutagenic responses are observed. The boundary between no effect and effect is represented by the no observable effect level (NOEL) and the lowest observable effect level (LOEL), and the threshold dose is statistically calculated where the slope of the graph first increases significantly.
by that agent. 
Linear dose-response relationships for genotoxins
In genetic toxicology a linear dose-response relationship has 48 long been assumed to apply for direct acting genotoxic agents 49 (Henderson et al., 2000) . Fig. 1 . Columns depict binucleate frequency as a measure of toxicity and clearly show no toxicity in this dose range. Here AHH1 cells were treated with increasing doses of EMS and especially large numbers of cells (up to 10,000 per dose) were assessed for micronuclei to increase the sensitivity of the assay and allow the dose-response to be truly examined. This data is taken from that published previously by ourselves (Doak et al., 2007) . EMS clearly does not induce chromosome breakage (line graph) at low dose levels (<1.3 g/ml), whereas at doses higher than this, chromosome damage is seen to increase. Simple statistical tests (one-way ANOVA with Dunnett's post hoc test) showed that 1.4 g/ml was the first dose showing significant genotoxicity, but more complex statistical modelling has identified 1.06 g/ml as the point of inflection in the dose-response and hence the threshold dose (Johnson et al., 2009 
Human variation in DNA repair and thresholds
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Given that DNA repair appears to be centrally involved in Rusin et al. (1999) old for a population might be impossible, due to genetic variation evidence is present in the literature that requires some resolution.
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Tissue specificity of DNA repair gene expression is also a compli- of some genes involved in BER (Fig. 3) highlighting the heterogene-
260
ity that is possible. Indeed in our studies (Fig. 3) , there appeared 261 Fig. 3 . Gene expression levels for DNA repair genes (MPG, APEX, XRCC1) in blood taken from healthy individuals. Expression levels (absolute mRNA levels, utilising a cloned target for standard curve generation) show considerable variation (8-250-fold) in the different individuals. Mpg shows least variation (8-fold), XRCC1 shows 125-fold variation, whilst APEX shows 250-fold variation in mRNA copy number. Some variation may be induced due to environmental exposures (smoking status, etc.) as well as host genetics. Data taken from paper recently submitted (Zaïr et al., submitted for publication). The dose-response for MT1 (repair deficient cells) is shifted to the left suggesting greater sensitivity to EMS. Indeed, the lowest observable effect level (LOEL) or the first dose giving a positive increase in mutation frequency is 1 g/ml for MT1 cells compare to 1.4 g/ml for AHH1 cells.
to be an 8- genotoxic thresholds is illustrated in Fig. 4 . Fig. 4 
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